Report overview
Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P?), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.
This report aims to provide a comprehensive presentation of the global market for Human Coagulation Factor VIII, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Coagulation Factor VIII. This report contains market size and forecasts of Human Coagulation Factor VIII in global, including the following market information:
Global Human Coagulation Factor VIII Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Human Coagulation Factor VIII Market Sales, 2018-2023, 2024-2029, (K Bottles)
Global top five Human Coagulation Factor VIII companies in 2022 (%)
The global Human Coagulation Factor VIII market was valued at US$ 10530 million in 2022 and is projected to reach US$ 15860 million by 2029, at a CAGR of 6.0% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Human Coagulation Factor VIII key players include Baxter, Bayer, CSL, Pfizer, Biogen, etc. Global top five manufacturers hold a share about 80%. North America is the largest market, with a share about 60%, followed by Europe, with a share about 30 percent. In terms of product, Recombinant Factor VIII is the largest segment, with a share about 65%. And in terms of application, the largest application is Hemophilia A, followed by Spontanous / Trauma, Surgical, etc.
We surveyed the Human Coagulation Factor VIII manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Coagulation Factor VIII Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Bottles)
Global Human Coagulation Factor VIII Market Segment Percentages, by Type, 2022 (%)
Recombinant Factor VIII
Plasma-derived Factor VIII
Global Human Coagulation Factor VIII Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Bottles)
Global Human Coagulation Factor VIII Market Segment Percentages, by Application, 2022 (%)
Hemophilia A
Spontanous / Trauma
Surgical
Other
Global Human Coagulation Factor VIII Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Bottles)
Global Human Coagulation Factor VIII Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Human Coagulation Factor VIII revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Human Coagulation Factor VIII revenues share in global market, 2022 (%)
Key companies Human Coagulation Factor VIII sales in global market, 2018-2023 (Estimated), (K Bottles)
Key companies Human Coagulation Factor VIII sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Shire (Baxter)
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Outline of Major Chapters:
Chapter 1: Introduces the definition of Human Coagulation Factor VIII, market overview.
Chapter 2: Global Human Coagulation Factor VIII market size in revenue and volume.
Chapter 3: Detailed analysis of Human Coagulation Factor VIII manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Human Coagulation Factor VIII in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Human Coagulation Factor VIII capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
